



EndoDrill®

Transforming cancer diagnostics
EndoDrill®, the first powered
EUS/EBUS biopsy system

October 29, 2025

Fredrik Lindblad, CEO


www.bibbinstruments.com



BIBB
INSTRUMENTS

Listed medtech innovator - Spotlight Market (BiBB)

Biopsy is the key to accurate diagnosis



Symptom

Biopsy sampling

Diagnosis

Treatment

Biopsy = the gateway to
correct cancer treatment

>1 million cancer patients
annually need more
reliable biopsy results

EUS/EBUS - essential tools in cancer diagnostics

Endoscopic/Endobronchial Ultrasound (EUS/EBUS)


Combines endoscopy and ultrasound to visualize and sample internal organs, essential in diagnosing cancers such as pancreatic and lung cancer.

~3.5M

GI & Lung Cancer Cases¹

~1.5M

EUS/EBUS
Biopsy Cases¹



1. ChatGPT-5 and MarketScan, 2022

EUS/EBUS ~1.5M procedures¹

Rapid global adoption of EUS and EBUS procedures

Some of the world's largest medtech companies' market EUS/EBUS **manually** operated needle instruments

Price: €200-500 per disposable instrument



EUS in the USA -
from 10,400 procedures
in 2000 to...

CAGR +17 %

↑ 28x since 2000

293,000 procedures in 2022
in the USA alone²

COOK
MEDICAL

OLYMPUS

Boston
Scientific



Medtronic

BIBB
INSTRUMENTS

1990s

EUS-FNA
Development

2000s

EUS-FNA
First commercial
instruments

2010s

EUS-FNB 1st Gen
2nd Gen
3rd Gen

2020s

EUS-CNB
EndoDrill®

1. Various sources, ChatGPT5 calculation

2. MarketScan Commercial Claims and Encounters and Medicare Supplemental database.

Key problems with today's manual biopsy needles

- **High diagnostic failure:** Real-world failure rates are likely around 20-30 %, resulting in numerous costly **repeat biopsy procedures** (\$5,000-8,000 each).¹
- **Poor tissue quality:** Samples are often **fragmented or blood-contaminated**, making histopathological evaluation difficult and more resource-intensive.²
- **Slow and inconsistent:** The manual, multi-pass is highly operator-dependent, adding time, variability, and patient discomfort.³
- **Not ready for precision medicine:** Standard needles often fail to provide **intact core tissue** suitable for molecular profiling and precision oncology.⁴

1. Chat GPT-5 (compiled literature summary, 2025)

2. Ceyhan AM et al., *Dig Endosc* 2019

3. ESGE Guideline, *Endoscopy* 2021

4. Levy MJ et al., *Gastrointest Endosc* 2021



Introducing EndoDrill® – powered EUS-CNB

Components:

Single-use

- 1 EndoDrill® Biopsy Instrument

Capital equipment: EndoDrill® Drive System

- 2 Motor unit
- 3 Drive cable
- 4 Foot pedal

1




2

4

3



Sampling of solid
"core" biopsies



EndoDrill® advantage at a glance

Standard needles



VS

Boston
Scientific
Medtronic
OLYMPUS
COOK®

EndoDrill®



Pitfalls with standard needles



-  Manual needle sticks
-  Blood-cells-tissue fragments - risk of repeated biopsy sampling
-  Requires 2-5 needle passes (international guidelines)
-  Not future-proof for precision medicine

Key Features EndoDrill®



-  High precision powered "drilling"
-  True core biopsies
-  Normally with only "one pass" (needle puncture)
-  Future-proof for precision medicine

Real-world case

49 y/o male in California


- 3.5 cm pancreatic lesion
- Benign or cancer?

Diagnosis

- ✗ 1st Manual EUS-FNB
- ✗ 2nd Manual EUS-FNB
- ✓ 3rd EndoDrill® GI
→ **Diagnostic** - confirmed pancreatic cancer


A failed EUS-FNA/FNB typically results in a repeat EUS biopsy costing US hospitals about \$5,000-8,000.¹

1. Calculation by ChatGPT-5




Core tissue makes the difference

The pathologist's view



Total addressable market \$1.5 billion



Clinical proof from Europe and U.S.

Study	Region	Publication year	Indication	N	Key Findings
Pilot Study		2024 ¹	Stomach (SEL)	7	100 % diagnostic accuracy in one single needle pass.
Clinical Case Series		2024 ²	Stomach, Pancreas	8	"Effective and safe", 100 % diagnostic accuracy in one single needle pass.
Retrospective Multicenter Study		2025 ³	Stomach, Pancreas	28	"Effective and safe". 80 % diagnostic in one single needle pass.
Case Series		2025 ⁴	Liver, Pancreas	4	"Safe and effective". 100 % diagnostic accuracy.
Case Study		2025 ⁵	Pancreas	3	Demonstrated the potential to provide high-quality PDAC tissue cores with reduced blood contamination compared with standard needles.


1-5: No serious adverse events (SAE) have been observed.

1. Swahn F *et al.* *Scand J Gastroenterol*, 2024 - Pilot study: first electric-driven EUS core biopsy.
2. Mendoza Ladd A *et al.* *Endoscopy Int Open*, 2024 - First clinical use of motorized EUS core biopsy.
3. Mendoza Ladd A *et al.* *Endoscopy*, 2025 - Multicenter experience with EndoDrill core needle biopsy.
4. Oliver M *et al.* Michigan GI Society Conf, 2025 - Liver biopsy case vignette using EndoDrill.
5. Vera Garcia DV *et al.* Mayo Clinic Research Day, 2025 - "Drill2Culture" PDAC ex vivo model from EndoDrill cores.



EndoDrill® GI vs SharkCore

Female 28 years, submucosal tumor (pilot study¹)



The paradigm shift from fine-needle aspiration (FNA) to core needle biopsy (CNB) has already occurred in breast and prostate diagnostics, and EndoDrill® aims to enable the same transformation within endoscopic ultrasound (EUS) biopsy.



Dr Robert Glavas in action

Positive clinical feedback from EU & US

2024-2025




- *This device will be a **game changer***"¹
- *FNB on **steroids!***"²
- *I'm more than **satisfied**...*"³
- *It has great potential to be implemented as a **first option** in any scenario where EUS-GTA is indicated.*"⁴
- *The use of the EndoDrill device demonstrated **strong diagnostic utility** across an array of clinical presentations...*"⁵



1. Dr Antonio Mendoza Ladd, 2. Dr Francisco Baldaque Silva, 3. Dr Tajana Pavic, 4. The American Journal of Gastroenterology 119(10S):p S2653, 5. Oliver M et al. (2025) EUS-guided motorized FNA ("EndoDrill") liver biopsy: case vignette. 4th Michigan GI Society Conf.

Durable and strong IP portfolio (-2041)

Patent family	Patent pending	Approved patent	Valid until
EndoDrill (powered, Gen 2)	Patent family 1		
	• Europe (EPC), filed in 2018	Europe I	2038
	• International application (PCT), filed 2019, national entry 2021	USA (NoA), Europe II, Japan, India, China	2039
	• Divisional application, filed 2023	Europe III	2039
	Patent family 2		
	• International application II (PCT), filed 2020, national entry 2022	Japan	2040
	Patent family 3		
	• International application III (PCT), filed in 2021, national entry 2022	China Japan (DtG)	2041




Year 2025 - filled with milestones




From clinical introduction to launch





Clinical introduction at 14 sites 2024 - 2025



Overall launch plan H2 2025 - 2026



Road Map



Future opportunities

Launch of EndoDrill® EBUS for lung cancer (2026)




EBUS-guided core biopsies with EndoDrill® EBUS may improve diagnostic yield and staging accuracy in lung cancer

EndoDrill® - Opening New Possibilities for Precision Oncology¹



“These preliminary observations suggest EndoDrill® may improve tissue acquisition quality compared with standard FNB techniques”¹



From EndoDrill® core biopsy to individualized cancer treatment
— enabling precision oncology

1. Mayo Clinic, Jacksonville FL (2025). "Drill2Culture - Establishing Ex Vivo PDAC Models via EndoDrill-Derived Core Biopsies Using EUS-Guided Biopsy."


Scalable Razor-Blade Model

- **Product Line:** 3 EndoDrill® Biopsy Instruments, all use the same Drive System
- **Distribution:** Global sales through exclusive distribution partners
- **Razor** = EndoDrill® System (capital equipment, one-time sale)
Blade = EndoDrill® Biopsy Instruments (single-use per patient)
- **Pricing:** \$700 - \$1,200 / procedure (end-customer ASP = \$700)
- **Total Gross Margin:** 70 % on single-use instrument (target)
- **TAM (units):** ~1.5M procedures
- **TAM (\$):** ~\$1.0 billion

Scenario 10 % global market share (combined BiBB + partner case)

- Assume ASP = \$700
- Total Revenue: ~\$100 million (est.)
- Total Gross Profit: ~\$70 million (est.)

Based on end-customer ASP (\$700). BiBB's revenues reflect distributor share; acquirers capture full system economics post-acquisition.



Management team

 Fredrik Lindblad • CEO • MSc ME, BSc BA • 632,162 shares • 200,000 warrants 23/28    	 Dr Charles Walther • Founder - CMO - Board member • Senior consultant in pathology and clinical cytology, MD, PhD • 3,540,000 shares • 100,000 warrants 23/28  	 Josefin Arborelius • R&D Director • MSc ME   	 Lotta Ljungberg • Director QA/RA • MSc Chemical Eng • 150,000 shares • 100,000 warrants 23/28      	 Dr Paul Rasmusson • Supply Chain Director • PhD Strategic Management • 261,256 shares     
---	--	---	--	---

Backed by reputed shareholders

Top-10: ~50% (Sep 30, 2025)

#	Owner	Shares	%	
1	CHWA AB (Founder Dr Charles Walther)	3 540 000	8,7%	
2	Tibia Konsult AB (Swedish Investment company)	3 004 548	7,4%	
3	Aktia Nordic Micro Cap (Finnish micro cap fund)	2 285 732	5,6%	
4	Svanberg & Co Invest AB + private (Håkan Svanberg, Swedencare)	1 992 634	4,9%	Top 5
5	Mastan AB (Håkan Lagerberg, CEO Swedencare)*	1 887 773	4,6%	31,2%
6	Lovisa Hamrin (Hamrin's Foundation/Herenco)	1 872 582	4,6%	
7	Gabriel Güner (FMF, Guner Holding, private)*	1 556 531	3,8%	
8	JCC Group Invest (Johan Bergdahl, Swedencare)	1 518 880	3,7%	
9	Life Science Invest Fund 1 APS (Danish life science fund)	1 337 475	3,3%	Top 10
10	Schroder Micro Cap Fund (fund, JP Morgan Lux)	1 020 000	2,5%	49,1%
	Others	20 723 147	50,9%	
	Sum	40 739 302	100,0%	

* The information may be uncertain as endowment - and pension insurances are not visible in the share register.

Why invest in BiBB Now?

-  Large and growing market in endoscopic cancer diagnostics
-  First-mover advantage - world's first powered EUS biopsy device
-  Proven clinical benefit - core tissue, one pass success
-  Scalable razor-blade business model
-  Commercial readiness - FDA&CE cleared, US launch 2025/26 (TaeWoong)
-  Strong IP and clear exit potential





Thank you!



fredrik.lindblad@bibbinstruments.com



+46 70 899 94 86



www.bibbinstruments.com

BIBB
INSTRUMENTS